• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Reunion Neuroscience Inc.

    7/7/23 4:30:14 PM ET
    $REUN
    Medical/Nursing Services
    Health Care
    Get the next $REUN alert in real time by email
    6-K 1 tm2320756d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13A-16 OR 15D-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2023

     

    Commission File Number 001-40635

     

     

    Reunion Neuroscience Inc. 

    (Exact name of Registrant as specified in its charter)

     

     

    N/A

    (Translation of Registrant’s name)

     

    30 Duncan Street, Lower North Suite
    Toronto, Ontario
    M5V 2C3
    1-833-833-1967
    (Address and telephone number of registrant’s principal executive offices)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ¨             Form 40-F x

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

     

     

     

     

     

    This report on Form 6-K is hereby incorporated by reference into (i) the Registration Statement on Form F-10 (File No. 333-261515) of Reunion Neuroscience Inc. (the “Company”), (ii) the Registration Statement on Form S-8 (File No. 333-268481) of the Company and (iii) the Registration Statement on Form S-8 (File No. 333-260071) of the Company, and in each instance the related prospectus, as such registration statements and prospectuses may be amended or supplemented from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Financial Statements and Exhibits 

     

    Exhibit  
       
    99.1 Annual Information Form for the Fiscal Year Ended March 31, 2023
    99.2 Management Discussion and Analysis for the Fiscal Years Ended March 31, 2023 and 2022
    99.3 Audited Annual Financial Statements for the Fiscal Years Ended March 31, 2023 and 2022

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Reunion Neuroscience Inc.
       
    Date: July 7, 2023 By:

    /s/ Edward F. Smith

        Name:Edward F. Smith
        Title:Chief Financial Officer

     

    3

     

    Get the next $REUN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $REUN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $REUN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement

      TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions and MPM BioImpact ("MPM") are pleased to announce the completion of the previously announced plan of arrangement (the "Arrangement") effective today, whereby MPM acquired Reunion in an all-cash transaction valued at approximately US$13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Pursuant to the terms and conditions of a definitive arrangement agr

      8/1/23 9:03:29 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

      TORONTO, July 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions is pleased to announce that, earlier today, the Ontario Superior Court of Justice (Commercial List) granted a final order approving the proposed arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, with affiliates of MPM BioImpact ("MPM"). As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2

      7/14/23 4:05:00 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement

      TORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX:REUN, NASDAQ:REUN) ("Reunion" or the "Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, is pleased to announce the voting results of the special meeting of shareholders of Reunion held yesterday, July 12, 2023 (the "Meeting"). At the Meeting, shareholders voted in favour of a special resolution (the "Arrangement Resolution") to approve the proposed plan of arrangement (the "Arrangement") under Section 192 of the Canada Business Corporations Act, whereby affiliates of MPM BioImpact would acquire Reu

      7/13/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Leadership Updates

    Live Leadership Updates

    See more
    • Reunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors

      - Seasoned Psychiatrist and Global Pharmaceutical R&D Executive with Over Two Decades of Experience in Clinical Development, Including at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb and Sunovion Pharmaceuticals TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed psychiatrist Fred Grossman, D.O., FAPA, to its Board of Directors. Dr. Grossman has over two decades of experience in clinical development and medical affairs, ph

      4/3/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Reunion Neuroscience Inc.

      15-12G - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/18/23 12:56:55 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form 6-K filed by Reunion Neuroscience Inc.

      6-K - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/1/23 10:54:08 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form F-10POS filed by Reunion Neuroscience Inc.

      F-10POS - Reunion Neuroscience Inc. (0001865482) (Filer)

      8/1/23 9:53:09 AM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Reunion Neuroscience Inc. (Amendment)

      SC 13D/A - Reunion Neuroscience Inc. (0001865482) (Subject)

      8/1/23 10:53:55 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by Reunion Neuroscience Inc.

      SC 13G - Reunion Neuroscience Inc. (0001865482) (Subject)

      6/20/23 4:06:16 PM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13D filed by Reunion Neuroscience Inc.

      SC 13D - Reunion Neuroscience Inc. (0001865482) (Subject)

      6/12/23 5:30:28 PM ET
      $REUN
      Medical/Nursing Services
      Health Care

    $REUN
    Financials

    Live finance-specific insights

    See more
    • Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

      Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022, Reunion Held CAD $32.4 Million in Cash and Cash Equivalents TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today provided a business update and re

      2/14/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care
    • Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

      TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company plans to release its business update and financial results for Reunion's fiscal 2023 third quarter ended December 31, 2022, before market open on Tuesday, February 14, 2023. The Company will hold a conference call and webcast to discuss its results at 8:30 a.m. ET the same day. To access the call, please dial 1-877-407-9716 (within the U.S.) or 1-201-493-6779 (outside the U.S.) and provide conferen

      2/2/23 7:30:00 AM ET
      $REUN
      Medical/Nursing Services
      Health Care